Investigators assessed disparities in patient access to therapies approved for the treatment of gastrointestinal malignancies in the United States, the United Kingdom, Europe, and Ireland, as well as benefit relative to cost.
Investigators compared the outcomes of patients who received pancreatic enzyme replacement therapy (PERT) with those who did not.
Wong et al analyzed the antitumor activity of ARB202, a Cadherin-17 (CDH17) and CD3-directed T-cell engager, in xenograft models.
This exploratory subgroup analysis of the TAGS study assessed the efficacy, safety, and quality of life (QOL) results observed in patients who received trifluridine/tipiracil or placebo in the third- or later-line settings.
The updated CR rate was 8.0% compared with 5.5% in the primary analysis.
Bernstam et al presented findings from an expansion cohort of a phase 1 trial testing the bispecific HER2-targeted antibody zanidatamab in patients with HER2-overexpressing biliary tract cancer.
Outcomes of lenvatinib-receiving patients who progressed to Child-Pugh B liver function within the first 8 weeks of treatment were compared with those of patients who maintained Child-Pugh A classification during the same time period.
Investigators present findings from a phase 1a study evaluating the safety and efficacy of MIV-818 in patients with hepatocellular carcinoma (HCC), hepatic cholangiocarcinoma (CCA), or liver metastases from solid tumors.
The phase 1b/2 PLANET study tested the combination of lanreotide and pembrolizumab in advanced well- or moderately differentiated gastroenteropancreatic neuroendocrine tumors (GEP-NETs).
Kasi et al compared a novel, artificial intelligence (AI)-based cancer clinical trial search tool with ClinicalTrials.gov to determine which afforded a better user experience.
